Laboratory Animal Diets Market is expected to reach US$ 2,987.79 Million by 2034

Rodents Segment Leading the Laboratory Animal Diets Market by Animal Type

According to our new research study on “Laboratory Animal Diets Market Forecast to 2034 – Global Analysis – by Animal Type, Diet Type, Form, Research Application and End User,” the Laboratory Animal Diets market size is expected to grow from US$ 2,300.94 million in 2025 to US$ 2,987.79 million by 2034, with a CAGR of 2.0% during 2025–2034. Market revenue growth in the laboratory animal diet market has been driven by increasing investments in biomedical research and expanding utilization of laboratory animals across oncology, immunology, microbiome, and metabolic disease studies. Greater demand for specialized, purified, and disease-model diets has been observed, while research activities have been supported through funding initiatives, academic publications, regulatory programs, company annual reports, investor presentations, and other publicly available scientific and corporate documents. 

Development of new gene editing tools, transgenic modeling, and techniques for reconstituting the human immune system allowed scientists to produce more precise animal models reflecting the physiology and disease mechanisms of humans. These models have found wide applications in oncology, immunology, infectious diseases, rare diseases, and advanced therapeutics where standard laboratory animals offer very limited translational utility. As the pharmaceutical and biotechnology pipeline is growing in complexity owing to the advent of cell therapies, gene therapies, and individualized treatments, there is increasing demand from research institutions for animal models which can deliver predictive and reliable results. Increased biological sensitivity of the modern models has made environmental control issues, including nutrition, extremely important.

The recent literature in Laboratory Animal Research published in BMC in April 2024 reiterates the fact that laboratory animal diets are actively biological modifiers and not just husbandry feed inputs, especially in advanced preclinical research models. It is important to note that such evidence suggests that diet plays an important role in the regulation of metabolism, immune signaling, and gut microbiome structure.

There has been an increased usage of genetically modified and humanized animals as models which have changed the buying preferences at research facilities, contract research organizations, and drug companies. Nutrient uniformity has become necessary since even small changes in diet composition affect immune reactions, metabolic pathways, microbiomes, and disease progression. Therefore, there is a greater need for pure, semi-pure, and custom-made laboratory animal diets which guarantee nutrient specifications and reduce batch variation.

Laboratory Animal Diets Market Analysis Based on Segmental Evaluation:

Based on animal type, the laboratory animal diets market is classified into rodents, rabbits, non-human primates (NHPs), canines, swine, others. In 2025, The majority market share within the laboratory animal diet market has been held by rodents due to their extensive utilization across biomedical, pharmaceutical, and academic research programs. Widespread adoption of mice, rats, and other rodent species has been observed in oncology, immunology, neuroscience, metabolic disease, toxicology, and genetic research owing to their well-characterized biology, short reproductive cycles, and suitability for controlled laboratory studies. 

The scope of the Laboratory Animal Diets market report includes an assessment of the market performance in North America, Europe, and Asia Pacific. In terms of revenue, North America dominated the laboratory animal diets market share in 2025. 

The pharmaceutical, biotechnology, and academia research sectors remain committed to advancing their work in the fields of gene therapy, cell therapy, oncology, and precision medicine. These research areas require controlled experiments and, therefore, the generation of reproducible results, and laboratory animal nutrition remains a key consideration for such study design. With the increase in understanding of the impact of diet on physiological responses, metabolic activity, immune response, and the disease process, the need for specialized laboratory animal diets increases. Diet has evolved from merely being a requirement for maintenance to a parameter that could potentially influence research outcomes and translation.

This evolution of research infrastructure has been demonstrated by the digital revolution in laboratory practices. The developments made in digital and computational pathology are increasingly being incorporated in preclinical research laboratories to integrate data and streamline laboratory workflows in the various stages of drug development. In March 2023, Proscia made strides in its expansion of services in the US$ 12 million preclinical research and development sector through the enhancement of its Concentriq for Research platform. The enhanced platform is aimed at standardizing data and laboratory workflows and supporting GLP and non-GLP drug safety studies. 

LabDiet, Inotiv(Teklad), Altromin International, SDS Diets, SSNIFF, SAFE, Mucedola, Dyets, Inc., Specialty Feeds, Research Diets, Inc are among the leading companies profiled in the laboratory animal diets market report. 

By animal type, the market is segmented into rodents (mice, rats, other rodents), rabbits, non-human primates (NHPs), canines, swine, and other laboratory animal species. Based on diet type, the market is segmented into standard laboratory diet, purified and semi-purified diet, specialty laboratory animal diet (disease model diet, gene and cell therapy research diet, microbiome research diet and personalized medicine diet), sterile diet and nutritional supplements and enrichment products. Based on the forms the market segmented into pellets, powder, liquid and others. By application market is segmented into oncology research, immunology and autoimmune research, microbiome research, metabolic disease research, gene therapy and cell therapy, personalized medicine, neuroscience research, infectious disease research and others. In terms of end users, the market is categorized into academic and research institutions, pharmaceutical and biopharmaceutical companies, CROs (contract research organizations) and others. By geography, the market is divided into North America (the US, Canada and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific).